Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

European Journal of Cancer - Tập 99 - Trang 28-36 - 2018
Thomas Brodowicz1,2, Olivier Mir3, Jennifer Wallet4, Antoine Italiano5,6, Jean-Yves Blay7,8, François Bertucci9, Wolfgang Eisterer10,2, Christine Chevreau11, Sophie Piperno-Neumann12, Emmanuelle Bompas13, Thomas Ryckewaert14, Bernadette Liegl-Antzwager15,2, Julien Thery4, Nicolas Penel4,14,16, Axel Le Cesne3, Marie-Cécile Le Deley4,17
1Department of Medicine /Oncology, Medical University of Vienna, General Hospital, Comprehensive Cancer Center – MusculoSkeletalTumorUnit, Währinger Gürtel 18-20, 1090 Vienna, Austria
2Sarcoma Platform Austria, Austria
3Department of Medical Oncology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800 Villejuif, France
4Department of Clinical Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59000 Lille, France
5Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France
6Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France
7Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
8Claude Bernard University Lyon 1, 43 boulevard du 11 novembre 1918, 69622, Villeurbanne cedex, France
9Department of Medical Oncology, Institut Paoli Calmette, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France
10Department of Internal Medicine, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020 Klagenfurt am Wörthersee, Austria
11Department of Medical Oncology, IUCT Oncopole, 1 Av. Irène Joliot-Curie, 31100 Toulouse, France
12Department of Medical Oncology, Institut Curie, 26 Rue d’Ulm, 75005, Paris, France
13Department of Medical Oncology, Centre René Gauducheau, St. Herblain, Saint-Herblain, France
14Department of Medical Oncology, Centre Oscar Lambret, Lille, France
15Institute of Pathology, Medical University of Graz, 8036 Graz, Austria
16Department of Medical Oncology, University Hospital, 3 rue Combemale, 59000 Lille, France
17Paris-Saclay University, Univ. Paris-Sud, CESP, INSERM, Gustave Roussy, 94805 Villejuif, France

Tài liệu tham khảo

ESMO/European Sarcoma Network Working Group, 2014, Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, iii102, 10.1093/annonc/mdu254

Blay, 2003, Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy, Eur J Cancer, 39, 64, 10.1016/S0959-8049(02)00480-X

Gough, 2011, Symptom burden, survival and palliative care in advanced soft tissue sarcoma, Sarcoma, 2011, 325189, 10.1155/2011/325189

Ratan, 2016, Chemotherapy for soft tissue sarcoma, Cancer, 122, 2952, 10.1002/cncr.30191

Mir, 2016, Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomized, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, 17, 1732, 10.1016/S1470-2045(16)30507-1

Texier, 2018, Evaluation of treatment effect with paired failure times in a a single-arm phase II trial in Oncology, Comput Math Meth Med, 2018, 10.1155/2018/1672176

Von Hoff, 1998, There are no bad anticancer agents, only bad clinical trial designs – twenty-first Richard and Hinda Rosenthal Award Lecture, Clin Cancer Res, 4, 1079

Cousin, 2013, Correlation between overall survival and growth modulation index in pretreated patients: a study from the French Sarcoma Group, Ann Oncol, 24, 2681, 10.1093/annonc/mdt278

Penel, 2013, Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy, Ann Oncol, 24, 537, 10.1093/annonc/mds470

Hensley, 2009, Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study, Gynecol Oncol, 115, 460, 10.1016/j.ygyno.2009.09.011

George, 2009, Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas, J Clin Oncol, 27, 3154, 10.1200/JCO.2008.20.9890

Sleijfer, 2009, J Clin Oncol, 27, 3126, 10.1200/JCO.2008.21.3223

Santoro, 2013, Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy, Ann Oncol, 24, 1093, 10.1093/annonc/mds607

Von Mehren, 2012, Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas, Cancer, 118, 770, 10.1002/cncr.26334

Pacey, 2011, Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial, Invest New Drugs, 29, 481, 10.1007/s10637-009-9367-9

Nakamura, 2016, The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanase MusculoSkletetal Oncology Group (JMOG) study, Cancer, 122, 1408, 10.1002/cncr.29961

Maruzzo, 2015, Pazopanib for soliatary fibrous tumours; the Royal Marsden Hospital experience, Clin Sarcoma Res, 5, 5, 10.1186/s13569-015-0022-2

Prasd, 2014, The misguided ethics of crossover trials, Contemp Clin Trials, 37, 167, 10.1016/j.cct.2013.12.003

Van der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized double-blind, placebo controlled phase 3 trial, Lancet Oncol, 379, 1879, 10.1016/S0140-6736(12)60651-5

Thông tin
Thông tin xuất bản

European Journal of Cancer

Tập 99

28-36

Thông tin tác giả